Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Investors Are Watching Venture Life Group plc (LSE:VLG) Closely — Here’s What Comes Next

The next stage will be judged by execution, financial conversion and further company-specific milestones.

Ankur Sharma | 10 November 2026

FTSE AIM All-Share Healthcare Watch: Ondine Biomedical (LSE:OBI) Highlights No Resistance After Repeated MB-aPDT Exposure

The immediate reason is clear: The study assessed 20 consecutive sub-lethal MB-aPDT exposure cycles. The tested strains included MRSA, VISA and LRSA. These details give investors a current reference point for measuring management’s progress. They also create a defined set of follow-up questions around …

Ankur Sharma | 09 November 2026

One Health Group (LSE:OHGR) Moves Into Focus After Fresh Major-Holder Disclosure

The stock is linked to the FTSE AIM All-Share, placing the company-specific news within a wider market context.

Ankur Sharma | 09 November 2026

RTW Biotech Opportunities (LSE:RTWG): $42.8m Buyback Pool Adds a New Twist to the Biotech M&A Story

• The company has returned $42.3 million of an original $45 million commitment to shareholders through buybacks.

Ankur Sharma | 09 November 2026

FTSE AIM All-Share Healthcare Watch: RUA Life Sciences (LSE:RUA) Shows Progress Despite Mixed Divisions

The immediate reason is clear: Revenue for the year ended 30 September 2026 is expected at about £5.5 million. Pre-tax profit is expected at about £4.7 million, largely reflecting a non-recurring accounting gain. These details give investors a current reference point for measuring management’s …

Ankur Sharma | 09 November 2026

Thalia Therapeutics (LSE:THAT): miRisten Trial Agreement Puts RNA Therapeutics Stock in Focus

Thalia Therapeutics is in focus on 9 November 2026 after signing a Clinical Trial Agreement with City of Hope for its miRisten programme. The agreement formalises completion and the budget for the Phase 1 dose-escalation study of THAT-001 in relapsed or refractory acute myeloid …

Ankur Sharma | 09 November 2026

FTSE AIM All-Share Healthcare Watch: Tristel (LSE:TSTL) Heads Into Mello2026 With Strategy in Focus

The immediate reason is clear: Tristel will present and exhibit at Mello2026 on 18 November. CEO Chris Lee and CFO Anna Wasyl are scheduled to present. These details give investors a current reference point for measuring management’s progress. They also create a defined set …

Ankur Sharma | 09 November 2026

FTSE AIM All-Share Healthcare Watch: Verici Dx (LSE:VRCI) Draws Attention After Major Holding Disclosure

The immediate reason is clear: A major holding notification showed Spreadex at 5.1893% when voting rights and financial instruments were combined. The notification was triggered after a threshold crossing on 29 October 2026. These details give investors a current reference point for measuring management’s …

Ankur Sharma | 09 November 2026

BEXIMCO Pharmaceuticals (LSE:BXP): Profit Jumps 31% as FY2026 Results Put Growth and Dividend in Focus

BEXIMCO Pharmaceuticals is in focus on 9 November 2026 after releasing results for the year ended 30 June. Revenue increased 14.5% to BDT 56.27bn, while profit after tax rose 30.9% to BDT 9.16bn. The results also showed stronger cash generation and a proposed cash …

Ankur Sharma | 09 November 2026

Cambridge Nutritional Sciences (LSE:CNSL) Moves Into Focus After Major Holder Crosses 5%

The stock is linked to the FTSE AIM All-Share, placing the company-specific news within a wider market context.

Ankur Sharma | 09 November 2026
Support

Hi! How can we help you today?

Loading…